Clinical Trials Browser

Phase 1/2 × cabozantinib × Plasma cell × Clear all

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 11 charts

Multiple Myeloma

NCT01866293 2017-08-30

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Phase 1/2 Completed

11 enrolled 12 charts

Multiple Myeloma, Recurrence